New Releases from NCBI BookshelfPembrolizumab (Keytruda): Therapeutic area: Advanced or metastatic malignant pleural mesothelioma (MPM): Reimbursement Review [Internet].Pembrolizumab (Keytruda): Therapeutic area: Advanced or metastatic malignant pleural mesothelioma (MPM): Reimbursement Review [Internet].

By admin / January 19, 2026

Post Content

New Releases from NCBI BookshelfNivolumab Plus Ipilimumab (Opdivo Plus Yervoy): Indication: Opdivo (nivolumab), in combination with ipilimumab, for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma: Reimbursement Recommendation [Internet].Nivolumab Plus Ipilimumab (Opdivo Plus Yervoy): Indication: Opdivo (nivolumab), in combination with ipilimumab, for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma: Reimbursement Recommendation [Internet].

New Releases from NCBI BookshelfAbemaciclib (Verzenio): Reimbursement request: For the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in females who are postmenopausal as initial endocrine-based therapy: Reimbursement Review [Internet].Abemaciclib (Verzenio): Reimbursement request: For the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor in females who are postmenopausal as initial endocrine-based therapy: Reimbursement Review [Internet].

Useful Links

NEWREDMARS SKILL AND RESEARCH FOUNDATION

Registration No: 771800548 Contact Number : +91-8249516996

Publication
Skill Development
Blog Writing

Research
Awareness Camp
Digital Research

Ngo Darpan
Service
Donation

Term and Condition
Privacy Policy
Disclaimer

Scroll to Top

Leave a Comment Cancel Reply

Useful Links

NEWREDMARS SKILL AND RESEARCH FOUNDATION

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.